Journal
SCIENCE ADVANCES
Volume 5, Issue 4, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.aav1388
Keywords
-
Categories
Funding
- KIST (Open Research Programs and Bridge Programs), Korea Health Industry Development Institute (KHIDI) [HI14C3319]
- National Research Foundation [NRF-2018R1A6A1A03023718, 2018R1D1A1B0704885]
- Asan Institute for Life Sciences [20160588]
- Yonsei University [2018-22-0022]
Ask authors/readers for more resources
Detection of amyloid-beta (A beta) aggregates contributes to the diagnosis of Alzheimer disease (AD). Plasma A beta is deemed a less invasive and more accessible hallmark of AD, as A beta can penetrate blood-brain barriers. However, correlations between biofluidic A beta concentrations and AD progression has been tenuous. Here, we introduce a diagnostic technique that compares the heterogeneous and the monomerized states of A beta in plasma. We used a small molecule, EPPS [4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid], to dissociate aggregated A beta into monomers to enhance quantification accuracy. Subsequently, A beta levels of EPPS-treated plasma were compared to those of untreated samples to minimize inter-and intraindividual variations. The interdigitated microelectrode sensor system was used to measure plasma A beta levels on a scale of 0.1 pg/ml. The implementation of this self-standard blood test resulted in substantial distinctions between patients with AD and individuals with normal cognition (NC), with selectivity and sensitivity over 90%.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available